Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…

Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.

Ovarian cancer

Oncology and palliative care · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Obstruction, torsion or acute compromise

Bowel obstruction, pleural respiratory failure, venous thrombosis, sepsis or acute adnexal torsion may precede complete cancer staging.

Action: Stabilise the acute syndrome, obtain urgent surgical or respiratory input and use contrast imaging; drain, decompress or operate for immediate danger while protecting tissue and the gynaecological oncology pathway.

Synopsis

Recognise persistent symptom patterns, use CA125 and ultrasound appropriately in primary care, establish specialist stage and tissue, and sequence cytoreductive surgery, platinum treatment, genetics and maintenance therapy.

  • Persistent frequent bloating, early satiety, pelvic pain or urinary urgency in an older woman warrants structured ovarian-cancer assessment.
  • A palpable pelvic mass or ascites requires urgent specialist referral; do not wait for CA125 before referring.
  • Without a mass, measure CA125 first and arrange pelvic and abdominal ultrasound when it is 35 units/mL or above.
  • Contrast CT stages suspected disease and estimates operability, but small peritoneal deposits can remain occult.
  • Obtain a core biopsy before neoadjuvant chemotherapy whenever safely feasible; CA125 and imaging are not histology.
  • Primary cytoreduction is preferred when complete macroscopic clearance is realistically achievable with acceptable morbidity.
  • Carboplatin–paclitaxel is the standard systemic backbone, followed by molecularly selected maintenance where indicated.
  • Offer germline testing at diagnosis and complete tumour BRCA or HRD testing early enough to guide maintenance treatment.

Key red flags

Persistent or frequent bloating, early satiety, pelvic or abdominal pain and urinary urgency occur especially in an older patient.

Ascites, a pelvic mass, nodularity or pleural effusion suggests advanced disease and needs urgent specialist assessment.

Vomiting, distension and obstipation suggests malignant bowel obstruction.

Sudden severe unilateral pelvic pain with nausea suggests torsion and requires emergency gynaecological review.

A first-degree family pattern of ovarian, early breast, pancreatic, prostate or Lynch-associated cancers raises inherited risk.

Rapid breathlessness, unilateral leg swelling or pleuritic pain suggests effusion or venous thromboembolism.

Bowel obstruction

Colic, vomiting, distension and failure to pass stool or flatus requires emergency assessment for level, perforation and reversibility.

Investigation priorities

01
Serum CA125 in primary careFirst step

Triage persistent compatible symptoms in women without an obvious pelvic mass or ascites.

Management branches

SymptomsUse CA125 and ultrasound without delay

A patient, especially aged 50 or over, reports persistent bloating, early satiety, pelvic pain or urinary frequency.

  1. Examine abdomen and pelvis; a mass or ascites warrants urgent referral rather than waiting for a marker.
  2. In primary care without an obvious mass, measure CA125 and arrange pelvic and abdominal ultrasound when it is 35 units/mL or above.
  3. Refer suspicious ultrasound urgently; if tests are normal but symptoms persist, investigate alternative gastrointestinal, urinary and gynaecological causes and safety-net.

Key medicines

Carboplatin with paclitaxelA standard epithelial ovarian regimen gives paclitaxel 175 mg/m² IV followed by carboplatin targeted at AUC 5–6 IV on day 1 every 21 days, usually for 6 cycles with protocolled adjustments.Calculate carboplatin from reliable GFR, use hypersensitivity precautions and antiemesis, and monitor counts, neuropathy, renal and liver function, infection and paclitaxel reactions before each cycle.
OlaparibUse 300 mg orally twice daily continuously as tablets, with interruption and reduction to 250 mg then 200 mg twice daily for toxicity according to the licensed indication and maintenance duration.Confirm the exact molecular and treatment indication, monitor blood count monthly early and then regularly, and investigate persistent cytopenia for myelodysplasia; review nausea, fatigue, renal function and interactions.
Open full textbook →Answer 2 questions
Sources and review status5 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • NICE CG122 ovarian cancer recognition and initial managementCurrent NICE recommendations for ovarian cancer recognition and initial management assessment and treatment.
  • British Gynaecological Cancer Society guidelinesUK specialist pathways for diagnosis and management of gynaecological malignancy.
  • Royal College of Pathologists cancer datasetsUK pathology sampling, staging, margin and molecular reporting standards.
  • BNF carboplatin, paclitaxel, olaparib, bevacizumab and enoxaparinUK prescribing, contraindication and monitoring information for carboplatin, paclitaxel, olaparib, bevacizumab and enoxaparin.
  • NICE ovarian cancer technology guidanceCurrent NHS recommendations for PARP inhibitors and other ovarian cancer treatments.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom